Engrail Therapeutics funding, investors and company details
Engrail Therapeutics is an emerging Pharmaceutical startup from [●], working in the space of Biotechnology and pharmaceutical company focused on neuroscience drug development. Founded by Vikram Sudarsan, Stephen Cunningham.
- Company: Engrail Therapeutics
- Sector: Pharmaceutical
- Location: [●]
- Founders: Vikram Sudarsan, Stephen Cunningham
- Total funding raised: ₹1,308.6 Cr
Company overview
Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing transformational therapies for neuropsychiatric and neurodevelopmental diseases — conditions that impact the brain and nervous system, including depression, schizophrenia, and other central nervous system (CNS) disorders. The company’s research and development efforts are centered on discovering and advancing drug candidates that can modify underlying biological processes in the brain to improve patients’ lives where existing treatments have limited effectiveness. Engrail pursues innovative small molecules and other therapeutic modalities designed to address unmet needs in neuroscience, with several compounds progressing through preclinical and clinical development. Its work also involves building intellectual property around proprietary chemical entities and targeting mechanisms involved in neuroplasticity, neurotransmitter modulation, and other CNS-relevant pathways, positioning Engrail as a potential future leader in precision neuroscience treatment.
Funding rounds
- Latest round (Series B): $ 157.00 Mn (₹1,308.60 Cr.), 2024-03-20. Investors: F-Prime, Forbion, Norwest Venture Partners, RiverVest Venture Partners, Red Tree Venture Capital, Ysios Capital, Longwood Fund, Eight Roads ventures, Pivotal Life Sciences